We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00907101
Recruitment Status : Completed
First Posted : May 22, 2009
Results First Posted : March 16, 2016
Last Update Posted : March 16, 2016
Sponsor:
Information provided by (Responsible Party):
Galderma Laboratories, L.P.

Brief Summary:
The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.

Condition or disease Intervention/treatment Phase
P Acnes Colonization Drug: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes
Study Start Date : June 2009
Primary Completion Date : July 2009
Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Antibiotics
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Study Treatment

Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)

Other Names:

Epiduo® Gel Apply once daily

Drug: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Apply once daily
Other Name: Epiduo® Gel



Primary Outcome Measures :
  1. Change From Baseline in Quantitative Bacteriology Measurements at Week 4 [ Time Frame: Week 4 ]
    Mean log10 values of P. acnes from swabbed skin samples Please note: Quantitative bacteriologic cultures were obtained from the facial skin (forehead) at screening, baseline, week 2 and week 4/early termination. Samples were obtained according to a modification of the technique of Williamson and Kligman. CFUs of P. acnes were counted at the dilution that contained between 10 and 100 CFUs. Total densities of P. acnes were calculated and reported as the average (of both plates) of the log10 CFUs per cm².


Secondary Outcome Measures :
  1. Worst Post Baseline Tolerability Assessment - Erythema [ Time Frame: Week 4 ]
    Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs.

  2. Worst Post Baseline Tolerability Assessment - Dryness [ Time Frame: Week 4 ]
    Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs.

  3. Worst Post Baseline Tolerability Assessment - Scaling [ Time Frame: Week 4 ]
    Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs.

  4. Worst Post Baseline Tolerability Assessment - Stinging/Burning [ Time Frame: Week 4 ]
    Please note: Tolerability assessments were recorded separately from adverse events. Tolerability changes which may have required a temporary or permanent interruption of the subject's participation in the study (at his/her request or at the investigator's discretion), or concomitant treatment, was to be recorded in the AE form of the CRF. An entry was to be made on the AE form for all AEs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy adult male or female subjects 18 years of age and older, with no past or present history of any significant internal disease
  • Subjects who:

    • show a high degree of fluorescence of the facial skin under a Wood's lamp, indicating the presence of P acnes
    • have Baseline P acnes count of > 10,000 per cm2 CFU of the facial skin (forehead)
    • have high level resistance to erythromycin, variable resistance to clindamycin, resistance to tetracycline and variable resistance to doxycycline and minocycline

Exclusion Criteria:

  • Subjects who exhibit any skin disorders of an acute or chronic nature (e.g., psoriasis, eczema, etc)
  • Subjects who have taken topical or systemic antibiotics within 4 weeks prior to baseline assessments
  • Subjects who have used other medications which may influence skin surface P acnes levels
  • Subjects who are unwilling to refrain from using toners, astringents or other drying agents on the face during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00907101


Locations
United States, Pennsylvania
Skin Study Center
Broomall, Pennsylvania, United States, 19008
Sponsors and Collaborators
Galderma Laboratories, L.P.
Investigators
Study Director: Ronald W Gottschalk, MD Galderma Laboratories, L.P.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Galderma Laboratories, L.P.
ClinicalTrials.gov Identifier: NCT00907101     History of Changes
Other Study ID Numbers: US10127
First Posted: May 22, 2009    Key Record Dates
Results First Posted: March 16, 2016
Last Update Posted: March 16, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Anti-Bacterial Agents
Benzoyl Peroxide
Adapalene
Adapalene, Benzoyl Peroxide Drug Combination
Anti-Infective Agents
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents